Dr.SUMIT, S17871
The study reports the 12 months outcomes of treatment naïve polypoidal choroidal vasculopathy (PCV) in 18 eyes with ≥20/40 best corrected visual acuity (BCVA). Patients were treated with monotherapy of anti vascular endothelial growth factors (VEGF) agents on a pro-re-nata (PRN) protocol. Photodynamic therapy using verteporfin (vPDT) was used as rescue therapy. The BCVA at baseline and 12 months were 0.16 ± 0.08 (Snellen equivalent 20/30) and 0.15 ± 0.15 logMAR (20/30) respectively. The (mean ± SD) CMT at baseline and 12 months were 188.2 ± 61.1µ and 161.7 ± 47.4µ (p=0.15) respectively. PED height at baseline was 393.2 ± 217.6µ which improved to 236.4 ± 215.1µ at 12 months (p=0.05). The mean(± SD) number of injections at 12 months were 3.28 ± 1.96 injections. A total of 3 eyes required vPDT (4 treatment sessions; mean: 1.33) as a rescue therapy through 12 months. The monotherapy of intravitreal anti VEGF injections can be an acceptable cost effective alternative in these eyes.
PRESENTATION NOT RECEIVED FROM THE AUTHOR.
Leave a Comment